A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Inclusion Criteria: * Patients with a histological diagnosis of locally advanced/metastatic HR+/HER2- breast cancer. Histological diagnosis does not necessarily origin from metastasis, but must reflect the most recent disease status * No prior systemic treatment for locally advanced/metastatic disease in the palliative setting * The treating physician has made the decision to treat the patient * with ribociclib in combination with an aromatase inhibitor or fulvestrant as initial treatment in first line, or * endocrine therapy as initial treatment in first line (e.g. letrozole, anastrozole, fulvestrant), or * chemotherapy as initial treatment in first line (e.g. taxanes, capecitabine, with or without bevacizumab) * Written informed consent of the patient * Patient who initiated treatment for first line no longer than 4 weeks (28 days) prior to written informed consent for this study * Planned treatment is in line with the respective current German SmPC ("Summary of product characteristics") * Patient is ≥18 years Exclusion Criteria: * Patients unable to provide written informed consent * Contra-indication according to the respective current German SmPC ("Summary of product characteristics"), as judged by the treating physician * The patient is currently under active treatment in an investigational study